These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 16467327)

  • 1. Neutralizing antibodies and persistence of immunity following anthrax vaccination.
    Hanson JF; Taft SC; Weiss AA
    Clin Vaccine Immunol; 2006 Feb; 13(2):208-13. PubMed ID: 16467327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralizing activity of vaccine-induced antibodies to two Bacillus anthracis toxin components, lethal factor and edema factor.
    Taft SC; Weiss AA
    Clin Vaccine Immunol; 2008 Jan; 15(1):71-5. PubMed ID: 18032590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anthrax Vaccine Precipitated Induces Edema Toxin-Neutralizing, Edema Factor-Specific Antibodies in Human Recipients.
    Dumas EK; Gross T; Larabee J; Pate L; Cuthbertson H; Charlton S; Hallis B; Engler RJM; Collins LC; Spooner CE; Chen H; Ballard J; James JA; Farris AD
    Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28877928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of a novel chimeric PALFn antigen of Bacillus anthracis and its immunological characterization in mouse model.
    Suryanarayana N; Verma M; Thavachelvam K; Saxena N; Mankere B; Tuteja U; Hmuaka V
    Appl Microbiol Biotechnol; 2016 Oct; 100(19):8439-51. PubMed ID: 27364624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of nasal immunization with protective antigen of Bacillus anthracis on protective immune response against anthrax toxin.
    Gaur R; Gupta PK; Banerjea AC; Singh Y
    Vaccine; 2002 Jun; 20(21-22):2836-9. PubMed ID: 12034111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selection and evaluation of the immunogenicity of protective antigen mutants as anthrax vaccine candidates.
    Yan M; Roehrl MH; Basar E; Wang JY
    Vaccine; 2008 Feb; 26(7):947-55. PubMed ID: 18192092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the human immune response to the UK anthrax vaccine.
    Baillie L; Townend T; Walker N; Eriksson U; Williamson D
    FEMS Immunol Med Microbiol; 2004 Oct; 42(2):267-70. PubMed ID: 15364114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring of ELISA-reactive antibodies against anthrax protective antigen (PA), lethal factor (LF), and toxin-neutralising antibodies in serum of individuals vaccinated against anthrax with the PA-based UK anthrax vaccine.
    Grunow R; Porsch-Ozcürümez M; Splettstoesser W; Buckendahl A; Hahn U; Beyer W; Böhm R; Huber M; vd Esche U; Bessler W; Frangoulidis D; Finke EJ
    Vaccine; 2007 May; 25(18):3679-83. PubMed ID: 17287051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies.
    Nguyen ML; Crowe SR; Kurella S; Teryzan S; Cao B; Ballard JD; James JA; Farris AD
    Infect Immun; 2009 Jan; 77(1):162-9. PubMed ID: 18981257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A plant based protective antigen [PA(dIV)] vaccine expressed in chloroplasts demonstrates protective immunity in mice against anthrax.
    Gorantala J; Grover S; Goel D; Rahi A; Jayadev Magani SK; Chandra S; Bhatnagar R
    Vaccine; 2011 Jun; 29(27):4521-33. PubMed ID: 21504775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection against anthrax by needle-free mucosal immunization with human anthrax vaccine.
    Zeng M; Xu Q; Pichichero ME
    Vaccine; 2007 May; 25(18):3588-94. PubMed ID: 17293013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid induced strong mucosal and systemic immunities.
    Sloat BR; Cui Z
    Pharm Res; 2006 Jun; 23(6):1217-26. PubMed ID: 16718616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores.
    Hermanson G; Whitlow V; Parker S; Tonsky K; Rusalov D; Ferrari M; Lalor P; Komai M; Mere R; Bell M; Brenneman K; Mateczun A; Evans T; Kaslow D; Galloway D; Hobart P
    Proc Natl Acad Sci U S A; 2004 Sep; 101(37):13601-6. PubMed ID: 15342913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax.
    Albrecht MT; Li H; Williamson ED; LeButt CS; Flick-Smith HC; Quinn CP; Westra H; Galloway D; Mateczun A; Goldman S; Groen H; Baillie LW
    Infect Immun; 2007 Nov; 75(11):5425-33. PubMed ID: 17646360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of delayed anthrax vaccine dose on Bacillus anthracis protective antigen IgG response and lethal toxin neutralization activity.
    Pittman PR; Fisher D; Quinn X; Schmader T; Barrera-Oro JG
    Vaccine; 2013 Oct; 31(44):5009-14. PubMed ID: 24026013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new triple chimeric protein as a high immunogenic antigen against anthrax toxins: theoretical and experimental analyses.
    Abdous M; Hasannia S; Salmanian AH; Shahryar Arab S; Shali A; Alizadeh GA; Hajizadeh A; Khafri A; Mohseni A
    Immunopharmacol Immunotoxicol; 2019 Feb; 41(1):25-31. PubMed ID: 30621469
    [No Abstract]   [Full Text] [Related]  

  • 17. Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein.
    Price BM; Liner AL; Park S; Leppla SH; Mateczun A; Galloway DR
    Infect Immun; 2001 Jul; 69(7):4509-15. PubMed ID: 11401993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxin-neutralizing antibodies elicited by naturally acquired cutaneous anthrax are elevated following severe disease and appear to target conformational epitopes.
    Dumas EK; Demiraslan H; Ingram RJ; Sparks RM; Muns E; Zamora A; Larabee J; Garman L; Ballard JD; Boons GJ; James JA; Kayabas U; Doganay M; Farris AD
    PLoS One; 2020; 15(4):e0230782. PubMed ID: 32294093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lethal factor antibodies contribute to lethal toxin neutralization in recipients of anthrax vaccine precipitated.
    Dumas EK; Garman L; Cuthbertson H; Charlton S; Hallis B; Engler RJM; Choudhari S; Picking WD; James JA; Farris AD
    Vaccine; 2017 Jun; 35(26):3416-3422. PubMed ID: 28504191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of three anthrax toxin neutralization assays.
    Ngundi MM; Meade BD; Lin TL; Tang WJ; Burns DL
    Clin Vaccine Immunol; 2010 Jun; 17(6):895-903. PubMed ID: 20375243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.